Shenzhen Venture Capital leads $28m Series B round in China’s Hrain Biotech

Shenzhen Venture Capital leads $28m Series B round in China’s Hrain Biotech

02 October, 2019

Hrain Biotechnology Shenzhen Venture Capital tumour immunotherapy

Printed by Unregistered user on Wed, 16 Jul 2025 23:29:43 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China’s SDIC, Shenzhen Venture Capital co-lead MabPlex’ $59m Series A

Read more from Greater China

Policy & Regulations

China vows to regulate ‘irrational’ competition in EV industry

Chinese AI firm MiniMax confidentially files for Hong Kong IPO